NVO

Novo Nordisk A/S Sponsored ADR (NVO) | Rumor.io

Novo Nordisk A/S

NVO

Attention (50-day avg)0.25%

Attention rank (50-day avg)#56

Bullish sentiment (50-day avg)48%

Price to earnings ratio9.69

Market capitalization171B

Earnings per share3.99

Dividend yield (TTM)2.99%

Revenue (annual)309.1B

Net income (annual)102.4B

Social

What share of all stock conversation is about NVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.14% -0.04	0.45% +0.22	0.31% +0.08	0.49% +0

Sep 29

Novo Nordisk A/S has entered into a license agreement with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist, HRS-1596, with a total potential deal value of up to $2.6 billion.
The deal includes a $300 million upfront payment and exclusive global rights outside mainland China.
The licensed drug is Phase 1-ready and has the potential for once-weekly oral dosing, with a focus on reducing weight and improving glycemic control.

Generated by AI

Sentiment

Of the messages about NVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	63.98% +43.07	59.82% +6.71	68.69% +29.08	80.15% +5.1
Bearish	36.02% -43.07	40.18% -6.71	31.31% -29.08	19.85% -5.1

Bullish· Sep 29

$NVO has a strong cash generation, with a 4.64% dividend yield and a low valuation at 9x earnings, making it an attractive buy opportunity.
The recent deal with Jiangsu Hengrui's oral obesity pill is a significant development, with Novo paying $300 million upfront and up to $2.6 billion in milestones and royalties, which could be a game-changer in the obesity treatment market.
Despite the market's negative sentiment and the stock's 70% decline from its highs, $NVO's fundamentals are too good to ignore, with a growing market for obesity treatments and a strong pipeline of products, making it a good asymmetrical bet.

Bearish· Sep 29

The company faces increasing competition, pricing pressure, and major patent expirations between 2030 and 2032, which may negatively impact its business.
Novo Nordisk's stock price has been stuck near multi-year lows, with broken trends and failed rallies, and the company has failed to regain its upward price momentum.
The company's recent news, such as a $2.6 billion licensing deal with Hengrui Pharma, has not been reflected positively in its stock price, and investors are becoming increasingly frustrated with its performance.

Generated by AI

Topics

Of the messages about NVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	0%	0.01%	15.67%	7.86%
Analysts	8.51%	45.91%	38.41%	33.83%
Announcements	81.28%	6.77%	5.66%	7.58%
Macro	4.68%	45.9%	36.37%	45.38%
Technical Analysis	5.53%	1.18%	3.69%	3.96%
Controversies	0%	0.22%	0.19%	1.39%

Earnings· Aug 5

Due to strong demand for Wegovy, Novo Nordisk A/S now expects 0%-6% revenue growth in FY 2026, up from a previous estimate of -6%.
Novo Nordisk's Q2 earnings beat expectations, with adjusted sales growing 7% and the company guiding to higher annual sales, driven by strong US sales.
Despite weaker-than-expected Oral Wegovy sales, Novo Nordisk's CEO defended the company's Q2 performance, citing a DKK 2.6B rebate adjustment that reduced reported sales growth to 3%, while adjusted sales grew 7%.

Analysts· May 12

Analysts are optimistic about Novo Nordisk's ($NVO) Wegovy, with higher-dose trials showing 27.7% average weight loss at 72 weeks and preserving muscle function.
Strong efficacy and a scalable oral/injectable ecosystem support $NVO's long-term potential, with analysts noting the company's ability to drive weight loss through its GLP-1 strategy.
Analysts have raised their price targets for $NVO, citing exceeding sales expectations and a strong future outlook, with some noting the company's partnerships with Eli Lilly and the potential for short squeeze activity.

Announcements· Sep 29

Novo Nordisk has entered into a license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.
The deal is worth up to $2.6 billion, with $300 million paid upfront, and grants Novo exclusive global rights outside mainland China.
Novo's U.S.-listed ADR closed at $38.71, and the company has a broad pipeline, but investors are currently focused on near-term deliverables.

Controversies· Jul 24

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Eli Lilly's advertising campaigns for its weight-loss and diabetes drugs, alleging the ads use misleading dose comparisons.
The lawsuit is seen as a necessary step by several Novo Nordisk investors, who view it as protecting the company's science, market share, and business in an increasingly competitive obesity market.
Novo Nordisk's pursuit of a preliminary injunction is seen as an attempt to regain control of the narrative in the obesity market, where Eli Lilly currently leads, and to defend its science and market position.

Macro· Jul 8

Novo Nordisk's valuation is disputed, with one commentator asserting it is not overvalued, while others have differing opinions on the company's value relative to others like Nike and PayPal.
The performance of Google, specifically its search function, is being questioned by some, who believe it may be outcompeted, a notion they attribute to the influence of AI chatbots.
Nike, PayPal, and Novo Nordisk are mentioned as potential investment opportunities, with one commentator expressing admiration for Nike and PayPal, but not Novo Nordisk.

Technical Analysis· Aug 25

$NVO is nearing a breakout at 308, which has previously acted as resistance, and a breach above this level could lead to a significant price increase.
The stock is currently at resistance, but a breakout above $50 could indicate a strong upward trend.
$NVO has formed a bullish chart pattern, including a double bottom, bullish island reversal, and a moving average crossover, which suggests a strong buy signal and potential for a significant price increase.

Generated by AI

Community

Of the messages about NVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80.73%	88.28%	63.46%	52.34%
Newcomers	19.27%	11.72%	36.54%	47.66%

Regulars· Sep 29

The recent licensing deal between Novo Nordisk and Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, has the potential for once-weekly oral dosing and a total deal value of up to $2.6 billion.
The deal strengthens Novo's pipeline and has the potential to improve weight and glycemic control, but investors are currently focused on near-term deliverables, according to Per Hansen at Nordnet.
The obesity story is not only about weight loss, but also encompasses diabetes, cardiovascular disease, and other obesity-related conditions, making it a broader healthcare story with potential for growth, according to bullish analysts.

Newcomers· Sep 29

The newcomers are focusing on Novo Nordisk's pipeline and its potential to bring new weight-loss medications to the market, with three new medications planned over the next three years.
They are also discussing the importance of long-term thinking and R&D for the company, with some arguing that Novo should focus on developing new drugs in-house rather than acquiring new candidates.
The newcomers are also analyzing the company's valuation and potential for rerating, with some pointing out that the market is undervaluing Novo due to perceived competition from GLP-1 drugs, but the newcomers see a beaten-down leader with strong cash generation and a deep obesity pipeline.

Generated by AI

News

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

1h agoreuters.com

Novo Nordisk Gives Uninspiring Outlook | The Motley Fool

Management is forecasting a considerable slowdown in its revenue growth.

7h agoThe Motley Fool

Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know

Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.

14h agoYahoo Finance UK

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist. Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk’s pipeline. The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients. The Hengrui oral GLP-1/GIP deal and new trial wins tell only part of the Novo Nordisk story. We have also...

16h agoYahoo Finance

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly

Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.

18h agoBenzinga

Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data

Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study

19h agoYahoo Finance

Also Discussed

Investors talking about NVO also mention

#	Name	Attention
1	Eli Lilly and CompanyLLY	0.16%+0.07
2	MTSR - Metsera, Inc.	——
3	Hims & Hers Health, Inc.HIMS	0.17%+0.1
4	UnitedHealth Group IncorporatedUNH	0%-0.02
5	Viking Therapeutics, Inc.VKTX	0.18%0
6	ASML Holding N.V. NY Registered SharesASML	0.01%-0.02
7	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
8	Duolingo, Inc. Class A Common StockDUOL	0.01%-0.01
9	dLocal LimitedDLO	0%new
10	Genmab A/S American Depositary SharesGMAB	0%0

Novo Nordisk A/S Sponsored ADR

Healthcare
Drug Manufacturers - General

Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.

Website

Location

Novo Alle 1

Bagsvaerd, 2880

Denmark

Social

What share of all stock conversation is about NVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.14% -0.04	0.45% +0.22	0.31% +0.08	0.49% +0

Sep 29

Novo Nordisk A/S has entered into a license agreement with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist, HRS-1596, with a total potential deal value of up to $2.6 billion.
The deal includes a $300 million upfront payment and exclusive global rights outside mainland China.
The licensed drug is Phase 1-ready and has the potential for once-weekly oral dosing, with a focus on reducing weight and improving glycemic control.

Generated by AI

Sentiment

Of the messages about NVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	63.98% +43.07	59.82% +6.71	68.69% +29.08	80.15% +5.1
Bearish	36.02% -43.07	40.18% -6.71	31.31% -29.08	19.85% -5.1

Bullish· Sep 29

$NVO has a strong cash generation, with a 4.64% dividend yield and a low valuation at 9x earnings, making it an attractive buy opportunity.
The recent deal with Jiangsu Hengrui's oral obesity pill is a significant development, with Novo paying $300 million upfront and up to $2.6 billion in milestones and royalties, which could be a game-changer in the obesity treatment market.
Despite the market's negative sentiment and the stock's 70% decline from its highs, $NVO's fundamentals are too good to ignore, with a growing market for obesity treatments and a strong pipeline of products, making it a good asymmetrical bet.

Bearish· Sep 29

The company faces increasing competition, pricing pressure, and major patent expirations between 2030 and 2032, which may negatively impact its business.
Novo Nordisk's stock price has been stuck near multi-year lows, with broken trends and failed rallies, and the company has failed to regain its upward price momentum.
The company's recent news, such as a $2.6 billion licensing deal with Hengrui Pharma, has not been reflected positively in its stock price, and investors are becoming increasingly frustrated with its performance.

Generated by AI

Topics

Of the messages about NVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	0%	0.01%	15.67%	7.86%
Analysts	8.51%	45.91%	38.41%	33.83%
Announcements	81.28%	6.77%	5.66%	7.58%
Macro	4.68%	45.9%	36.37%	45.38%
Technical Analysis	5.53%	1.18%	3.69%	3.96%
Controversies	0%	0.22%	0.19%	1.39%

Earnings· Aug 5

Due to strong demand for Wegovy, Novo Nordisk A/S now expects 0%-6% revenue growth in FY 2026, up from a previous estimate of -6%.
Novo Nordisk's Q2 earnings beat expectations, with adjusted sales growing 7% and the company guiding to higher annual sales, driven by strong US sales.
Despite weaker-than-expected Oral Wegovy sales, Novo Nordisk's CEO defended the company's Q2 performance, citing a DKK 2.6B rebate adjustment that reduced reported sales growth to 3%, while adjusted sales grew 7%.

Analysts· May 12

Analysts are optimistic about Novo Nordisk's ($NVO) Wegovy, with higher-dose trials showing 27.7% average weight loss at 72 weeks and preserving muscle function.
Strong efficacy and a scalable oral/injectable ecosystem support $NVO's long-term potential, with analysts noting the company's ability to drive weight loss through its GLP-1 strategy.
Analysts have raised their price targets for $NVO, citing exceeding sales expectations and a strong future outlook, with some noting the company's partnerships with Eli Lilly and the potential for short squeeze activity.

Announcements· Sep 29

Novo Nordisk has entered into a license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.
The deal is worth up to $2.6 billion, with $300 million paid upfront, and grants Novo exclusive global rights outside mainland China.
Novo's U.S.-listed ADR closed at $38.71, and the company has a broad pipeline, but investors are currently focused on near-term deliverables.

Controversies· Jul 24

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Eli Lilly's advertising campaigns for its weight-loss and diabetes drugs, alleging the ads use misleading dose comparisons.
The lawsuit is seen as a necessary step by several Novo Nordisk investors, who view it as protecting the company's science, market share, and business in an increasingly competitive obesity market.
Novo Nordisk's pursuit of a preliminary injunction is seen as an attempt to regain control of the narrative in the obesity market, where Eli Lilly currently leads, and to defend its science and market position.

Macro· Jul 8

Novo Nordisk's valuation is disputed, with one commentator asserting it is not overvalued, while others have differing opinions on the company's value relative to others like Nike and PayPal.
The performance of Google, specifically its search function, is being questioned by some, who believe it may be outcompeted, a notion they attribute to the influence of AI chatbots.
Nike, PayPal, and Novo Nordisk are mentioned as potential investment opportunities, with one commentator expressing admiration for Nike and PayPal, but not Novo Nordisk.

Technical Analysis· Aug 25

$NVO is nearing a breakout at 308, which has previously acted as resistance, and a breach above this level could lead to a significant price increase.
The stock is currently at resistance, but a breakout above $50 could indicate a strong upward trend.
$NVO has formed a bullish chart pattern, including a double bottom, bullish island reversal, and a moving average crossover, which suggests a strong buy signal and potential for a significant price increase.

Generated by AI

Community

Of the messages about NVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80.73%	88.28%	63.46%	52.34%
Newcomers	19.27%	11.72%	36.54%	47.66%

Regulars· Sep 29

The recent licensing deal between Novo Nordisk and Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, has the potential for once-weekly oral dosing and a total deal value of up to $2.6 billion.
The deal strengthens Novo's pipeline and has the potential to improve weight and glycemic control, but investors are currently focused on near-term deliverables, according to Per Hansen at Nordnet.
The obesity story is not only about weight loss, but also encompasses diabetes, cardiovascular disease, and other obesity-related conditions, making it a broader healthcare story with potential for growth, according to bullish analysts.

Newcomers· Sep 29

The newcomers are focusing on Novo Nordisk's pipeline and its potential to bring new weight-loss medications to the market, with three new medications planned over the next three years.
They are also discussing the importance of long-term thinking and R&D for the company, with some arguing that Novo should focus on developing new drugs in-house rather than acquiring new candidates.
The newcomers are also analyzing the company's valuation and potential for rerating, with some pointing out that the market is undervaluing Novo due to perceived competition from GLP-1 drugs, but the newcomers see a beaten-down leader with strong cash generation and a deep obesity pipeline.

Generated by AI

Novo Nordisk A/S

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 5

Analysts· May 12

Announcements· Sep 29

Controversies· Jul 24

Macro· Jul 8

Technical Analysis· Aug 25

Regulars· Sep 29

Newcomers· Sep 29

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

Novo Nordisk Gives Uninspiring Outlook | The Motley Fool

Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly

Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data

Also Discussed

Novo Nordisk A/S Sponsored ADR

Company Information

Location

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

Novo Nordisk Gives Uninspiring Outlook | The Motley Fool

Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly

Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 5

Analysts· May 12

Announcements· Sep 29

Controversies· Jul 24

Macro· Jul 8

Technical Analysis· Aug 25

Regulars· Sep 29

Newcomers· Sep 29